|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alireza M, Amelot A, Chauvet D, Terrier
LM, Lot G and Bekaert O: Poor prognosis and challenging in
treatment of optic nerve malignant gliomas: A literature review and
case report series. World Neurosurg. 97:751.e1–751.e6. 2017.
View Article : Google Scholar
|
|
4
|
Ashby LS, Smith KA and Stea B: Gliadel
wafer implantation combined with standard radiotherapy and
concurrent followed by adjuvant temozolomide for treatment of newly
diagnosed high-grade glioma: A systematic literature review. World
J Surg Oncol. 14:2252016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo E and Liu X: Overexpression of SCUBE2
inhibits proliferation, migration, and invasion in glioma cells.
Oncol Res. 25:437–444. 2017. View Article : Google Scholar
|
|
6
|
Liu ZJ, Liu HL, Zhou HC and Wang GC: TIPE2
inhibits hypoxia-Induced Wnt/β-catenin pathway activation and EMT
in glioma cells. Oncol Res. 24:255–261. 2016. View Article : Google Scholar
|
|
7
|
Li Z, Xu C, Gao M, Ding B, Wei X and Ji N:
Reduced expression of Jumonji, AT-rich interactive domain 2
(JARID2) in glioma inhibits tumor growth in vitro and in vivo.
Oncol Res. 25:365–372. 2017. View Article : Google Scholar
|
|
8
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ambros V: microRNAs: Tiny regulators with
great potential. Cell. 107:823–826. 2001. View Article : Google Scholar
|
|
12
|
Song H, Zhang Y, Liu N, Wan C, Zhang D,
Zhao S, Kong Y and Yuan L: miR-92b regulates glioma cells
proliferation, migration, invasion, and apoptosis via PTEN/Akt
signaling pathway. J Physiol Biochem. 72:201–211. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei J, Nduom EK, Kong LY, Hashimoto Y, Xu
S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, et al: miR-138
exerts anti-glioma efficacy by targeting immune checkpoints. Neuro
Oncol. 18:639–648. 2016. View Article : Google Scholar :
|
|
14
|
Shi L, Fei X, Wang Z and You Y: PI3K
inhibitor combined with miR-125b inhibitor sensitize TMZ-induced
anti-glioma stem cancer effects through inactivation of
Wnt/beta-catenin signaling pathway. In Vitro Cell Dev Biol Anim.
51:1047–1055. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liang ML, Hsieh TH, Ng KH, Tsai YN, Tsai
CF, Chao ME, Liu DJ, Chu SS, Chen W, Liu YR, et al: Downregulation
of miR-137 and miR-6500-3p promotes cell proliferation in pediatric
high-grade gliomas. Oncotarget. 7:19723–19737. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu J, Xu J, Li H, Sun C, Yu L, Li Y, Shi
C, Zhou X, Bian X, Ping Y, et al: miR-146b-5p functions as a tumor
suppressor by targeting TRAF6 and predicts the prognosis of human
gliomas. Oncotarget. 6:29129–29142. 2015.PubMed/NCBI
|
|
17
|
Wang J, Li Y and Jiang C: miR-133b
contributes to arsenic-induced apoptosis in U251 glioma cells by
targeting the hERG channel. J Mol Neurosci. 55:985–994. 2015.
View Article : Google Scholar
|
|
18
|
Liu H, Song Z, Liao D, Zhang T, Liu F,
Zheng W, Luo K and Yang L: miR-503 inhibits cell proliferation and
invasion in glioma by targeting L1CAM. Int J Clin Exp Med.
8:18441–18447. 2015.
|
|
19
|
Wang CY, Zhang JJ, Hua L, Yao KH, Chen JT
and Ren XQ: MicroRNA-98 suppresses cell proliferation, migration
and invasion by targeting collagen triple helix repeat containing 1
in hepatocellular carcinoma. Mol Med Rep. 13:2639–2644. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang G, Zhang X and Shi J: miR-98 inhibits
cell proliferation and invasion of non-small cell carcinoma lung
cancer by targeting PAK1. Int J Clin Exp Med. 8:20135–20145.
2015.
|
|
21
|
Li F, Li XJ, Qiao L, Shi F and Liu W, Li
Y, Dang YP, Gu WJ, Wang XG and Liu W: miR-98 suppresses melanoma
metastasis through a negative feedback loop with its target gene
IL-6. Exp Mol Med. 46:e1162014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Du Y, Li Y, Lv H, Zhou S, Sun Z and Wang
M: miR-98 suppresses tumor cell growth and metastasis by targeting
IGF1R in oral squamous cell carcinoma. Int J Clin Exp Pathol.
8:12252–12259. 2015.
|
|
23
|
Chen Z, Cheng Q, Ma Z, Xi H, Peng R and
Jiang B: Overexpression of RKIP inhibits cell invasion in glioma
cell lines through upregulation of miR-98. BioMed Res Int.
2013:6951792013. View Article : Google Scholar
|
|
24
|
Fan YH, Ye MH, Wu L, Lv SG, Wu MJ, Xiao B,
Liao CC, Ji QK, Chai Y and Zhu XG: Overexpression of miR-98
inhibits cell invasion in glioma cell lines via downregulation of
IKKε. Eur Rev Med Pharmacol Sci. 19:3593–3604. 2015.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
26
|
Chen X, Vega VB and Ng HH: Transcriptional
regulatory networks in embryonic stem cells. Cold Spring Harb Symp
Quant Biol. 73:203–209. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Forghanifard MM, Ardalan Khales S,
Javdani-Mallak A, Rad A, Farshchian M and Abbaszadegan MR: Stemness
state regulators SALL4 and SOX2 are involved in progression and
invasiveness of esophageal squamous cell carcinoma. Med Oncol.
31:9222014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Xu Z, Xu X, Zhang B, Wu H, Wang
M, Zhang X, Yang T, Cai J, Yan Y, et al: SALL4, a novel marker for
human gastric carcinogenesis and metastasis. Oncogene. 33:5491–500.
2014. View Article : Google Scholar
|
|
29
|
Han SX, Wang JL, Guo XJ, He CC, Ying X, Ma
JL, Zhang YY, Zhao Q and Zhu Q: Serum SALL4 is a novel prognosis
biomarker with tumor recurrence and poor survival of patients in
hepatocellular carcinoma. J Immunol Res. 2014:2623852014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deng G, Zhu L, Huang F, Nie W, Huang W, Xu
H, Zheng S, Yi Z and Wan T: SALL4 is a novel therapeutic target in
intrahepatic cholangiocarcinoma. Oncotarget. 6:27416–27426. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang L, Yan Y, Jiang Y, Cui Y, Zou Y,
Qian J, Luo C, Lu Y and Wu X: The expression of SALL4 in patients
with gliomas: High level of SALL4 expression is correlated with
poor outcome. J Neurooncol. 121:261–268. 2015. View Article : Google Scholar
|
|
32
|
Zhou W, Zou B, Liu L, Cui K, Gao J, Yuan S
and Cong N: MicroRNA-98 acts as a tumor suppressor in
hepatocellular carcinoma via targeting SALL4. Oncotarget.
7:74059–74073. 2016. View Article : Google Scholar : PubMed/NCBI
|
